STOCK TITAN
  1. Home
  2. Sec-filings
  3. ANAB
  4. [Form 4] ANAPTYSBIO, INC Insider Trading Activity

AnaptysBio (NASDAQ: ANAB) grants options and RSUs to director Schmid

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

AnaptysBio, Inc. reported a Form 4 for director John P. Schmid detailing new equity compensation awards. On January 6, 2026, he received a stock option covering 5,500 shares of common stock with an exercise price of $43.91 per share. This option vests in equal monthly installments of 1/12 starting February 6, 2026, so long as he continues providing service to the company.

Schmid was also granted 4,000 restricted stock units (RSUs), each representing the right to receive one share of AnaptysBio common stock for no cash payment. These RSUs vest 100% on the date of the company’s 2027 annual meeting of shareholders, contingent on his continued service through that date.

Positive

  • None.

Negative

  • None.
Insider Schmid John P.
Role Director
Type Security Shares Price Value
Grant/Award Stock Option (right to buy) 5,500 $0.00 --
Grant/Award Restricted Stock Unit 4,000 $0.00 --
Holdings After Transaction: Stock Option (right to buy) — 5,500 shares (Direct); Restricted Stock Unit — 4,000 shares (Direct)
Footnotes (1)
  1. The stock option vests as to 1/12 of the total shares monthly commencing on Februray 6, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2027 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Schmid John P.
(Last) (First) (Middle)
C/O ANAPTYSBIO, INC.
10770 WATERIDGE CIRCLE, SUITE 210
(Street)
SAN DIEGO CA 92121
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
ANAPTYSBIO, INC [ ANAB ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
01/06/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy) $43.91 01/06/2026 A 5,500 (1) 01/05/2036 Common Stock 5,500 $0 5,500 D
Restricted Stock Unit (2) 01/06/2026 A 4,000 (3) (3) Common Stock 4,000 $0 4,000 D
Explanation of Responses:
1. The stock option vests as to 1/12 of the total shares monthly commencing on Februray 6, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
2. Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
3. The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2027 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
/s/ Eric Loumeau, Attorney-in-Fact 01/08/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did ANAB report for John P. Schmid?

The company reported that director John P. Schmid received a stock option for 5,500 shares and 4,000 RSUs of AnaptysBio common stock on January 6, 2026.

What are the terms of John P. Schmid’s new stock options at AnaptysBio (ANAB)?

Schmid’s stock option covers 5,500 shares at an exercise price of $43.91 per share and vests as to 1/12 of the shares monthly starting February 6, 2026, subject to continued service.

How do the 4,000 RSUs granted to John P. Schmid by ANAB vest?

The 4,000 RSUs vest as to 100% of the units on the date of AnaptysBio’s 2027 annual meeting of shareholders, if Schmid continues to serve the company through that date.

What does each RSU granted to John P. Schmid by AnaptysBio represent?

Each RSU represents a contingent right to receive 1 share of AnaptysBio common stock upon settlement for no consideration.

Is John P. Schmid’s ownership reported as direct or indirect in this ANAB Form 4?

The filing reports Schmid’s ownership of the 5,500 stock options and 4,000 RSUs as direct.

What is the expiration date of John P. Schmid’s new stock options at AnaptysBio?

The stock option granted to Schmid expires on January 5, 2036, if not earlier exercised or terminated under its terms.